Press Release
Category Added in a WPeMatico Campaign
-
Business Wire2 March 2026
NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)
NEW YORK–(BUSINESS WIRE)–The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined…
Read More » -
Cision PR Newswire2 March 2026YY Group Malaysia Subsidiary to Grow Retail Promoter Workforce Fivefold, Targeting US$14 Million in 2026 Revenue
Strategic Expansion Deepens Retail Sector Penetration, Strengthening and Diversifying Revenue Pipeline SINGAPORE, March 2, 2026 /PRNewswire/ — YY Group Holding…
Read More » -
Cision PR Newswire2 March 2026
Spinogenix Announces FRAXA Research Foundation Support for PIs Leading Phase 2b Trial of Investigational Therapy SPG601 for People with Fragile X Syndrome (FXS)
SPG601 is a first-in-class, BK-modulator with the potential to improve cognitive, emotional and sensory symptoms in FXS patients LOS ANGELES,…
Read More » -
Cision PR Newswire2 March 2026XTI Aerospace’s Drone Nerds Business Expands Creality Line with New SPARKX i7 3D Printer
AI-assisted setup and operation, integrated filament switching system provide accessible out-of-the-box experience ENGLEWOOD, Colo., March 2, 2026 /PRNewswire/ — XTI…
Read More » -
Cision PR Newswire2 March 2026Cellebrite Completes Acquisition of Drone Forensics Leader SCG Canada, Inc.
Addition of Unmanned Aerial Vehicle (UAV) forensic capabilities extends Cellebrite’s AI-powered platform to one of the fastest-growing data sources in…
Read More » -
Cision PR Newswire2 March 2026Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to…
Read More » -
Cision PR Newswire2 March 2026Xtalks Announces its Life Science Webinar Calendar for March 2026
Upcoming free, educational webinars from Xtalks will feature topics in cell and gene therapy, clinical trials, commercialization & HEOR, drug…
Read More » -
Cision PR Newswire2 March 2026
AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn’s Disease
In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn’s disease, risankizumab (SKYRIZI®) achieved superiority for the…
Read More » -
Cision PR Newswire2 March 2026Jack Henry Executives Set to Speak at Upcoming Investor Conferences
MONETT, Mo., March 2, 2026 /PRNewswire/ — Jack Henry® (Nasdaq: JKHY) announced today that it will be participating in several upcoming…
Read More » -
Cision PR Newswire2 March 2026Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 4.474 Million Tokens, and Total Crypto and Total Cash Holdings of $9.9 Billion
Bitmine has 3,040,483 staked ETH, representing $6.0 billion at $1,976 per ETH; MAVAN staking solution on track to launch Q1…
Read More »